Literature DB >> 20501842

Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling.

Maya Shmulevitz1, Lu-Zhe Pan, Katy Garant, Da Pan, Patrick W K Lee.   

Abstract

Reovirus is the first naturally occurring human virus reported to exploit activated Ras signaling in the host cell for infection, and is currently undergoing clinical trials as a cancer therapeutic. Recent evidence suggests that Ras transformation promotes three reoviral replication steps during the first round of infection: uncoating of the incoming virion, generation of progeny viruses with enhanced infectivity, and virus release through enhanced apoptosis. Whether oncogenic Ras also enhances reovirus spread in subsequent rounds of infection through other mechanisms has not been examined. Here, we show that compared with nontransformed cells, Ras-transformed cells are severely compromised not only in their response to IFN-beta, but also in the induction of IFN-beta mRNA following reovirus infection. Defects in both IFN-beta production and response allow for efficient virus spread in Ras-transformed cells. We show that the MEK/ERK pathway downstream of Ras is responsible for inhibiting IFN-beta expression by blocking signaling from the retinoic acid-inducible gene I (RIG-I) which recognizes viral RNAs. Overexpression of wild-type RIG-I restores INF-beta expression in reovirus-infected Ras-transformed cells. In vitro-synthesized viral mRNAs also invoke robust RIG-I-mediated IFN-beta production in transfected nontransformed cells, but not in Ras-transformed cells. Collectively, our data suggest that oncogenic Ras promotes virus spread by suppressing viral RNA-induced IFN-beta production through negative regulation of RIG-I signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501842     DOI: 10.1158/0008-5472.CAN-09-4676

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis.

Authors:  Maya Shmulevitz; Shashi A Gujar; Dae-Gyun Ahn; Adil Mohamed; Patrick W K Lee
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Nogo to IFN by Ras.

Authors:  Maya Shmulevitz; Adil Mohamed
Journal:  Cell Cycle       Date:  2015-06-23       Impact factor: 4.534

4.  Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.

Authors:  Adil Mohamed; Carmit Teicher; Sarah Haefliger; Maya Shmulevitz
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

Review 5.  Systems biology unravels interferon responses to respiratory virus infections.

Authors:  Andrea L Kroeker; Kevin M Coombs
Journal:  World J Biol Chem       Date:  2014-02-26

Review 6.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

Review 7.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

8.  Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.

Authors:  Megan Moerdyk-Schauwecker; Nirav R Shah; Andrea M Murphy; Eric Hastie; Pinku Mukherjee; Valery Z Grdzelishvili
Journal:  Virology       Date:  2012-12-14       Impact factor: 3.616

Review 9.  Type I interferon: friend or foe?

Authors:  Giorgio Trinchieri
Journal:  J Exp Med       Date:  2010-09-13       Impact factor: 14.307

10.  Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency In Vitro and In Vivo.

Authors:  Adil Mohamed; Derek R Clements; Shashi A Gujar; Patrick W Lee; James R Smiley; Maya Shmulevitz
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.